Publication: Botulinum toxin injection for hypertonicity of the upper extremity within 12 weeks after stroke: A randomized controlled trial
Issued Date
2012-09-01
Resource Type
ISSN
15526844
15459683
15459683
Other identifier(s)
2-s2.0-84866318841
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Neurorehabilitation and Neural Repair. Vol.26, No.7 (2012), 812-821
Suggested Citation
Raymond L. Rosales, Keng He Kong, Khean Jin Goh, Witsanu Kumthornthip, Vincent Chung Tong Mok, Mary Mildred Delgado-De Los Santos, Karen Sui Geok Chua, Saini Jeffery Bin Freddy Abdullah, Benjamin Zakine, Pascal Maisonobe, Axel Magis, K. S.Lawrence Wong Botulinum toxin injection for hypertonicity of the upper extremity within 12 weeks after stroke: A randomized controlled trial. Neurorehabilitation and Neural Repair. Vol.26, No.7 (2012), 812-821. doi:10.1177/1545968311430824 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/14678
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Botulinum toxin injection for hypertonicity of the upper extremity within 12 weeks after stroke: A randomized controlled trial
Abstract
Background. Botulinum neurotoxin type A (BoNT-A) reduces upper-extremity poststroke spasticity when given 6 or more months after stroke. Effects on functional use of the arm and hand are less apparent. Objective. To determine the effect and safety of very early use of BoNT-A for patients with upper-limb spasticity. Methods. The Asia Botulinum Toxin-A Clinical Trial Designed for Early Post-stroke Spasticity (ABCDE-S; NCT00234546) was a multicenter, randomized, placebo-controlled trial conducted in patients recruited within 2 -12 weeks of first-ever stroke. Participants with a Modified Ashworth Scale (MAS) score of 1+ or above received BoNT-A (Dysport) 500 U or placebo to one or more wrist and elbow mover muscles, plus unstructured rehabilitation. The primary outcome was the MAS score in the most affected joint 4 weeks after first injection. Follow-up was 24 weeks. Results. A total of 163 patients were enrolled and assigned to placebo (n = 83) or BoNT-A (n = 80). Mean time since stroke was about 7 weeks. At 4 weeks postinjection, BoNT-A significantly improved MAS scores. Treatment effect-size estimates increased with higher baseline MAS scores from 0.45 (Q1) to 0.70 (Q3). MAS scores for all secondary end points improved with BoNT-A versus placebo at all time points (P < .0001, all visits). The Functional Motor Assessment Scale did not reveal clinically significant differences. No group differences in adverse events were found. Interpretation. BoNT-A 500 U can provide a sustained reduction in poststroke upper-limb spasticity when combined with rehabilitation in Asian patients who have mild-to-moderate hypertonicity and voluntary movement, within 2 -12 weeks of stroke. Functional use of the arm and hand was not affected. © The Author(s) 2012.